SCHEMBL1007089

SCHEMBL1007089

CC(C)(C)OC(=O)c1c[nH]c2ccc(N)cc12

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 9/20 0.50
HPGD P15428 1/20 0.45
CYP2C19 P33261 1/20 0.45
CREBBP Q92793 1/20 0.43
F7 P08709 1/20 0.41
F3 P13726 1/20 0.41
LMNA P02545 2/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
MITF O75030 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6511301 0.89 NR4A2 (0.50) NR4A2CREBBPMAPT
SCHEMBL6991795 0.84 NR4A2 (0.51) NR4A2HPGDCREBBPLMNAMAPT
SCHEMBL617202 0.84 NR4A2 (0.70) NR4A2HPGDCYP2C19CREBBPF7
SCHEMBL15557355 0.83 KDM4E (0.54) NR4A2HPGDCREBBPMAPTKMT2A
SCHEMBL4375343 0.83 GABRG2 (0.53) NR4A2CREBBPF7F3LMNA
SCHEMBL6986880 0.83 NR4A2 (0.72) NR4A2CREBBP
SCHEMBL6699986 0.83 NR4A2 (0.72) NR4A2F7F3
SCHEMBL5960313 0.82 HSD17B10 (0.50) NR4A2HPGDCREBBPF7F3
SCHEMBL6630345 0.82 NR4A2 (0.49) NR4A2HPGDCREBBPF7F3
SCHEMBL6629905 0.81 NR4A2 (0.46) NR4A2HPGDCREBBPF7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107835814-A Azabenzimidazoles and their use as ampa receptor modulators 詹森药业有限公司 2018-03-23 CN disclosed
EP-2268631-A1 AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
WO-2009118254-A1 AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-10-01 WO disclosed